Improvements With Pegloticase Plus MTX in Uncontrolled Gout Improvements With Pegloticase Plus MTX in Uncontrolled Gout
Learn more about the benefits of pegloticase used in combination with methotrexate for the treatment of uncontrolled gout.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

NIHR Alert: A pause in methotrexate treatment boosted the immune response to the COVID-19 vaccine
Commentaries provided on study which found people who paused methotrexate for 2 weeks immediately after their booster had better immune response to vaccine, but with temporary worsening of their condition and more flare ups, mostly managed at home. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 27, 2023 Category: Consumer Health News Source Type: news

75 Years: A Look Back on Methotrexate's Fascinating History 75 Years: A Look Back on Methotrexate's Fascinating History
Dr David Warmflash recounts how the meandering path of early research into chemotherapy for hematologic malignancies later led to methotrexate ' s importance for immune-mediated inflammatory diseases.Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2023 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news

FDA approves Roche ’s Actemra for the treatment of COVID-19 in hospitalised adults
Actemra is the first FDA-approved monoclonal antibody to treat COVID-19Since the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra worldwideActemra is approved for this use in more than 30 countries for the treatment of COVID-19Basel, 21 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ® (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalised adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasi...
Source: Roche Media News - December 21, 2022 Category: Pharmaceuticals Source Type: news

Addition of Immunomodulators Cuts Vascular Inflammation in RA
MONDAY, Dec. 12, 2022 -- For patients with rheumatoid arthritis (RA), the addition of a tumor necrosis factor (TNF) inhibitor (TNFi) or addition of sulfasalazine and hydroxychloroquine (triple therapy) to methotrexate results in clinically important... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2022 Category: Pharmaceuticals Source Type: news

A fatal fate: a medical error leading to acute methotrexate toxicity - Khan S, Batool W, Naveed S, Ahmad SM.
Methotrexate is an anti-metabolite, which is commonly utilized as an anti-cancer, anti-rheumatic, and anti-inflammatory drug used to treat a large variety of connective tissue disorders. Methotrexate when consumed at low doses for longer periods usually ha... (Source: SafetyLit)
Source: SafetyLit - December 1, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ACR: Holding Methotrexate for Just a Week After Flu Vaccine Works for RA Patients
FRIDAY, Nov. 18, 2022 -- For patients with rheumatoid arthritis (RA), temporarily discontinuing methotrexate for one week is noninferior to discontinuation for two weeks after seasonal flu vaccination to induce an immediate and long-term... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2022 Category: Pharmaceuticals Source Type: news

Combination Therapy May Boost Remission in JIA Combination Therapy May Boost Remission in JIA
Three-year outcome data from the STOP-JIA study showed that early methotrexate plus a biologic may aid remission and disease inactivity in pediatric polyarticular juvenile idiopathic arthritis.MDedge News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 17, 2022 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Twelve-Month Data Back Pegloticase-Methotrexate Gout Combo
(MedPage Today) -- PHILADELPHIA -- Previous findings that adding methotrexate to pegloticase (Krystexxa) in patients with gout was more effective than pegloticase alone have now been extended to a full year of treatment. At month 12 in the randomized... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 13, 2022 Category: Primary Care Source Type: news

New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Pediatric AD Study Compares Ciclosporin and Methotrexate Pediatric AD Study Compares Ciclosporin and Methotrexate
The findings are important, since many regulatory bodies require patients to try first-line conventional systemic therapies before novel therapeutics, the lead investigator explained.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2022 Category: Consumer Health News Tags: Dermatology News Source Type: news

Methotrexate Pause Enhances Vaccine Immunity Against Omicron Methotrexate Pause Enhances Vaccine Immunity Against Omicron
Researchers in Germany report a 10-day post-vaccination hold on methotrexate boosts immunity against Omicron without compromising safety or risk of disease flares.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 20, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Isotretinoin, Methotrexate Prescribing Concerns Post-Roe v. Wade Isotretinoin, Methotrexate Prescribing Concerns Post-Roe v. Wade
With abortion banned or greatly restricted in many states, dermatologists who prescribe isotretinoin and methotrexate said they are anxious about the future.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 13, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

MTX to Increase Response in Gout Receiving Pegloticase MTX to Increase Response in Gout Receiving Pegloticase
Might the addition of methotrexate help increase pegloticase treatment response in patients with uncontrolled gout?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news